Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues
B Arun, EP Frenkel - Expert opinion on pharmacotherapy, 2001 - Taylor & Francis
Topoisomerase I (topo-I) inhibitors are a new class of anticancer agents with a mechanism
of action aimed at interrupting DNA replication in cancer cells, the result of which is cell …
of action aimed at interrupting DNA replication in cancer cells, the result of which is cell …
Topotecan–a novel topoisomerase I inhibitor: pharmacology and clinical experience
C Kollmannsberger, K Mross, A Jakob, L Kanz… - Oncology, 1999 - karger.com
Topotecan, a water-soluble analogue of camptothecin, is a newly available cytotoxic agent
which acts as an inhibitor of topoisomerase I, an enzyme necessary for DNA replication …
which acts as an inhibitor of topoisomerase I, an enzyme necessary for DNA replication …
Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor
Purpose A phase I study with topotecan (SKF 104864-A, NSC 609699), a semisynthetdc
analog of camptothecin, was performed using a daily-times-5 regimen, given iv q 3 weeks, to …
analog of camptothecin, was performed using a daily-times-5 regimen, given iv q 3 weeks, to …
A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days
JG Wall, HA Burris III, DD Von Hoff, G Rodriguez… - Anti-cancer …, 1992 - journals.lww.com
Abstract Topotecan (SK&F 104864) is a novel antitumor agent whose mechanism of action
is inhibition of the DNA unwinding protein topoisomerase I. An analog of camptothecin …
is inhibition of the DNA unwinding protein topoisomerase I. An analog of camptothecin …
Topoisomerase I inhibitors: review and update
ML Rothenberg - Annals of Oncology, 1997 - Elsevier
This review presents a summary of precinical and clinical data on the topoisomerase I (topo
I) inhibitors that are under clinical development. To date, all of the topo I inhibitors that have …
I) inhibitors that are under clinical development. To date, all of the topo I inhibitors that have …
Toxicity of the topoisomerase I inhibitors
K Seiter - Expert Opinion on Drug Safety, 2005 - Taylor & Francis
The topoisomerase I inhibitors represent a class of antineoplastic agents with a wide
spectrum of activity against malignancies. Currently available topo-isomerase I inhibitors are …
spectrum of activity against malignancies. Currently available topo-isomerase I inhibitors are …
Clinical pharmacokinetics of topotecan
VMM Herben, WW ten Bokkel Huinink… - Clinical …, 1996 - Springer
Topotecan (Hycamtin®), a semisynthetic water-soluble derivative of camptothecin, is a
potent inhibitor of DNA topoisomerase I in vitro and has demonstrated encouraging …
potent inhibitor of DNA topoisomerase I in vitro and has demonstrated encouraging …
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
EK Rowinsky, LB Grochow, CB Hendricks… - Journal of clinical …, 1992 - ascopubs.org
PURPOSE A phase I and pharmacologic study was undertaken to determine the maximum-
tolerated dose (MTD), describe the principal toxicities, and characterize the pharmacologic …
tolerated dose (MTD), describe the principal toxicities, and characterize the pharmacologic …
Topoisomerase I inhibitors: topotecan and irenotecan
Camptothecin is a plant alkaloid extract from the Camptotheca acumminata tree, which is
cultivated throughout Asia (1). In the early 197Os, camptothecin demonstrated antineoplastic …
cultivated throughout Asia (1). In the early 197Os, camptothecin demonstrated antineoplastic …
Topoisomerase I inhibitors
RB Ewesuedo, MJ Ratain - The oncologist, 1997 - academic.oup.com
Topoisomerase I inhibitors are a new class of anticancer agents with a mechanism of action
aimed at interrupting DNA replication in cancer cells, the result of which is cell death. Most if …
aimed at interrupting DNA replication in cancer cells, the result of which is cell death. Most if …